Liu Huixin, Wei Xiaofang, He Yang, Pan Sijia, Wang Chenchen, Cheng Junze, Zhao Qiyuan, Shi Kaichuang, Si Hongbin
College of Animal Science and Technology, Guangxi Key Laboratory of Animal Breeding, Disease Control and Prevention, Guangxi grass station, Guangxi University, Nanning, 530004, Guangxi, China.
College of Animal Science and Technology, Guangxi Key Laboratory of Animal Breeding, Disease Control and Prevention, Guangxi grass station, Guangxi University, Nanning, 530004, Guangxi, China; Guangxi Center for Animal Disease Control and Prevention, Nanning 530001, China.
Poult Sci. 2025 May;104(5):104956. doi: 10.1016/j.psj.2025.104956. Epub 2025 Mar 1.
Infectious bronchitis virus (IBV) is a major pathogen that causes significant economic losses in the global poultry industry. Current vaccination strategies provide only partial protection, highlighting the need for more effective prevention and treatment methods. This study aimed to develop a novel compound throat anti-viral (CTA) from natural plants using data from the Traditional Chinese Medicine Inheritance System and identification through liquid chromatography-mass spectrometry. CTA demonstrated substantial anti-IBV effects both in vitro and in vivo studies. In vitro, CTA significantly inhibited IBV multiplication and alleviated the pathological lesions in chicken embryonic kidney cells, tracheal rings, and chicken embryos. In vivo, a seven-day treatment with CTA obtained much milder clinical signs, enhanced growth performance, and better immune organ indices in infected chickens. Additionally, CTA treatment reduced IBV levels in the trachea and lungs and increased specific antibody titers. CTA also maintained body homeostasis, exhibiting strong antioxidant and anti-inflammatory properties that mitigated respiratory tract damage. Metabolomics and network pharmacology analyses, revealed that CTA's antiviral effects are mediated through the FoxO signaling pathway. This study successfully developed an effective prescription database based on the Traditional Chinese Medicine Inheritance System and validated the antiviral efficacy of CTA through comprehensive in vitro and in vivo experiments. The findings elucidated the mechanisms of CTA's action, particularly through the FoxO signaling pathway, and highlighted its potential for clinical application as a novel antiviral treatment for IBV in the poultry industry.
传染性支气管炎病毒（IBV）是一种主要病原体，在全球家禽业中造成重大经济损失。当前的疫苗接种策略仅提供部分保护，这凸显了对更有效预防和治疗方法的需求。本研究旨在利用来自中医传承系统的数据并通过液相色谱-质谱法进行鉴定，从天然植物中开发一种新型复方咽喉抗病毒剂（CTA）。CTA在体外和体内研究中均显示出显著的抗IBV作用。在体外，CTA显著抑制IBV增殖，并减轻鸡胚肾细胞、气管环和鸡胚中的病理损伤。在体内，用CTA治疗七天后，感染鸡的临床症状明显减轻，生长性能增强，免疫器官指数更佳。此外，CTA治疗降低了气管和肺中的IBV水平，并提高了特异性抗体滴度。CTA还维持了机体稳态，表现出强大的抗氧化和抗炎特性，减轻了呼吸道损伤。代谢组学和网络药理学分析表明，CTA的抗病毒作用是通过FoxO信号通路介导的。本研究成功基于中医传承系统开发了一个有效的方剂数据库，并通过全面的体外和体内实验验证了CTA的抗病毒疗效。研究结果阐明了CTA的作用机制，特别是通过FoxO信号通路，并突出了其作为家禽业中治疗IBV的新型抗病毒药物的临床应用潜力。
